GSK’s Quad Flu Vaccine Clears FDA; B-Strain Protection Gap Could Drive Adoption
This article was originally published in The Pink Sheet Daily
Executive Summary
About one-third of the influenza B viruses tested this year are from the strain not included in this season’s trivalent vaccine; GlaxoSmithKline’s Fluarix is the second approved seasonal flu vaccine to protect against four virus strains, and by next season half of the U.S. manufacturers could be offering a broader spectrum product.
You may also be interested in...
Quadrivalent FluMist Clears FDA But Won’t Be On The Market Until 2013
MedImmune does not expect improved sales of the intranasal vaccine based on the enhanced formulation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.